Get started
Author

Nichola O Awosika

Observed names: N. Awosika, N.O. Awosika, Nichola Awosika
OpenAlex ID: A5094022835
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
2025 · Alessio Cortellini, Leonardo Brunetti, et al. · Journal for ImmunoTherapy of Cancer · 30
PDF
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
2025 · Amin H. Nassar, Chul Kim, et al. · Nature Communications · 20
PDF
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
2025 · Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, et al. · JHEP Reports · 10
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma
2024 · Bernardo Stefanini, Giulia F. Manfredi, et al. · Expert Review of Gastroenterology & Hepatology · 8
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
2025 · Bernardo Stefanini, Claudia Fulgenzi, et al. · Journal of Hepatocellular Carcinoma · 6
534 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
2024 · Alessio Cortellini, Edoardo Garbo, et al. · Regular and Young Investigator Award Abstracts · 2
P4.11E.17 Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade
2024 · B. Ricciuti, L. Hong, et al. · Journal of Thoracic Oncology · 1
PDF
Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.
2024 · Amin Nassar, Kelsey Matteson, et al. · Journal of Clinical Oncology · 1
PDF
3190eP Prognostic value of unplanned hospital attendances in early phase cancer trial participants
2025 · P. Lombardi, M. Filetti, et al. · Annals of Oncology
P3.13C.09 First-Line Treatments for Advanced Pure Large Cell Neuroendocrine Tumors (LCNEC):Insights from a Global Clinico-Genomic Study
2024 · A.H. Nassar, K. Matteson, et al. · Journal of Thoracic Oncology
PDF
THU-471-YI From randomised clinical trials to clinical practice: a systematic reviewand meta-analysis of real-word data on atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
2024 · Giulia Francesca Manfredi, Claudia Fulgenzi, et al. · Journal of Hepatology
112P Measuring time-toxicity and prognostic impact of hospital attendance in early phase cancer trials participants
2024 · N.O. Awosika, A. Maleki, et al. · ESMO Open
Works count: 12
Citation count: 77
H-index: 5
I10-index: 3
Year
Topic
Type